ProSolus is doubling down on its efforts to expand the utilization of transdermal drug delivery technologies. With the support of its parent, Mission Pharmacal, ProSolus has expanded its manufacturing capabilities and placed an increased emphasis on overall commercialization efforts. ProSolus, a wholly owned subsidiary of Mission, offers custom development and manufacturing of transdermal and trans-mucosal drug delivery products to treat a variety of health conditions. Acquired by Mission in ...